About US
Contact us
-
Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatideAfter plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking to protect its investment by wading into a lawsuit that seeks to allow co2024/12/31
-
After phase 3 setbacks, troubled Marinus inks $151M sale to Immedica PharmaMarinus Pharmaceuticals, working through a tumultuous period marked by two phase 3 blows, layoffs and a shareholder lawsuit, has inked an end-of-year sale to Immedica Pharma AB worth $151 million. Wi2024/12/31
-
Pfizer, BMS and more ring in 2025 with fresh round of drug price increases: reportWhile the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on the magnitude of cost increases getting rolled out Jan. 1. All told, drugmak2024/12/27
-
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous versionAlmost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in the U.S., the agency has cleared an under-the-skin version of the cancer2024/12/27
-
Lilly's Zepbound scores 2nd approval with landmark FDA nod in obstructive sleep apneaChristmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity star Zepbound. With the FDA’s green light on Friday,Lilly’s dual GIP/GLP-12024/12/24
-
Mirroring Merck's problem, GSK's Jemperli-Zejula study in ovarian cancer misses survival goalPerhaps PD-1 inhibitors just aren’t for ovarian cancer after all. Days after Merck & Co. posted a disappointing result on patient survival from its PD-1/PARP combination of Keytruda and Lynparza2024/12/24
-
A 'pivotal moment': Ionis enters next phase of commercial evolution with Tryngolza's FDA approvalWith an FDAapprovalfor Tryngolza (olezarsen) to treat the rare genetic disorder familial chylomicronemia syndrome (FCS), Ionis Pharmaceuticals enters a new era. While Ionis has gained several FDA nod2024/12/19
-
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffsThe FDA hasdoubled downon its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding pharmacies will have to halt producti2024/12/19
-
After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapyAn FDA advisory panel vote of 9-1 torecommendthe approval of Mesoblast Limited’s graft versus host disease (GVHD) cell therapy was a cruel tease for the Australian company. More than four years later2024/12/17
-
Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidationIn a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German cancer biotech it acquired earlier this year. Novartis confirmed Thur2024/12/17